Scholarlink

Purpose <p>Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.</p> Methods <p>A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.</p> Results <p>From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 − 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.</p> Conclusion <p>In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period

  • 期刊论文

  • 发表日期：

    2025年8月13日

查看全文
  • Oscar Arrieta,
  • Alexandra Díaz-Alba,
  • Sergio Moreno-Jiménez,
  • Alejandro Rodríguez-Camacho,
  • Enrique Caballe-Pérez,
  • Marco Antonio Rodríguez-Florido,
  • Alberto González-Aguilar,
  • Ytel Garcilazo-Reyes,
  • Mónica Alicia Sierra-del-Río,
  • Fernando Alcides Lozano-Sánchez,
  • Bernardo Cacho-Díaz

摘要

Purpose

Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.

Methods

A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.

Results

From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 − 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.

Conclusion

In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.